Since ErbB2 remained continuously expressed in a panel of breast cancer cell lines treated with either agent (Fig. 1a–c; Supplementary Fig. 1A,B), and no substantial increase in internalization nor degradation of ErbB2 was observed (Supplementary Fig. 1C–F), we inspected the phosphostatus of ErbB2 as well as of ErbB3. The gene discussed is ERBB2; the disease is breast cancer.